可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Sabroe I, Read RC, Whyte MK, el al. Toll-like receptors in health and disease: complex questions remain[J]. J Immunol, 2003, 171(4):1630-1635.[2] Gobert AP, Bambou JC., Werts C, et al. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentia-tion factor 88-independent mechanism[J]. J Biol chem, 2004, 279(1):245-250.[3] Triantafilou M, Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide[J]. Biochem Soc trans, 2004, 32(Pt 4):636-639.[4] Zhao ZQ, Zang YM. Alternative cardioprotective strategy during reperfusion: postconditioning vs preconditioning[J]. 心脏杂志, 2006,18(1):1-7,13.[5] Chong AJ, Shimamoto A, Hampton CR, et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart[J]. J Thorac cardiovasc surg, 2004, 128(2):170-179.[6] Li C, Ha T, Kelley J, et al. Modulating Toll-like receptor mediated signaling by (1-->3)-beta-D-glucan rapidly induces cardioprotection[J]. Cardiovasc res, 2004, 61(3):538-547.[7] Mullarkey M, Rose JR, Bristal J, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist[J]. J pharmacol exp ther, 2003, 304(3):1093-1102.[8] Wong YN, Rossignol D, Rose J R, et al. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study[J]. J clin pharmacol, 2003, 43(7):735-742.